Anzeige
Mehr »
Login
Sonntag, 02.10.2022 Börsentäglich über 12.000 News von 678 internationalen Medien
Dem ultimativen Durchbruch nah? – Breaking News: Bahnbrechende Methode
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWVB ISIN: US83548R2040 Ticker-Symbol: H3D0 
Stuttgart
30.09.22
21:48 Uhr
1,495 Euro
0,000
0,00 %
1-Jahres-Chart
SONNET BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4701,54030.09.

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee216Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly...
► Artikel lesen
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
21.09.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report4
21.09.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010548The SB101 and SB102 studies have together dosed 19 subjects to dateThis early review of safety sets the stage for further dose escalationAdditional safety and cytokine-specific data are expected during...
► Artikel lesen
20.09.XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 20.09.2022405The following instruments on XETRA do have their first trading 20.09.2022 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.09.2022 Aktien 1 CA15956X1096 Charbone Hydrogen Corp. 2...
► Artikel lesen
19.09.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.09.20221.891The following instruments on Boerse Frankfurt do have their last trading day on 19.09.2022Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.09.2022ISIN NameCA6034652041 MINEWORX...
► Artikel lesen
19.09.XFRA ISIN CHANGE315Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen IAU000000DLC0 Moab Minerals Ltd. 19.09.2022 AU0000240764 Moab Minerals Ltd. 20.09.2022 Tausch 1:1US83548R1059 Sonnet...
► Artikel lesen
19.09.Sonnet BioTherapeutics (SONN) Stock: 1-For-14 Reverse Split Goes Into Effect3
19.09.XFRA H3D: AUSSETZUNG/SUSPENSION233DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSONNET BIOTH.H.I.DL-...
► Artikel lesen
16.09.Sonnet BioTherapeutics (SONN) Stock: 1-For-14 Reverse Stock Split Announced4
16.09.Sonnet BioTherapeutics announces 1-for-14 reverse stock split2
16.09.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report-
16.09.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split366PRINCETON, NJ / ACCESSWIRE / September 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
► Artikel lesen
05.09.Mode Designs' Sonnet 65 feels almost too luxurious to type on3
25.08.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report3
15.08.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update517Initiation of two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumorsPositive preclinical data of SON-1010 combined with anti-PD1 Checkpoint InhibitionSubsequent...
► Artikel lesen
22.07.Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia2
22.07.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy371Sonnet's first clinical trial with SON-080 is a Phase 1b/2a double-blind, randomized controlled trialThis trial is expected to provide safety data compared to previous IL-6 products, along with preliminary...
► Artikel lesen
21.07.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers962Represents Sonnet's second clinical trial with SON-1010Study expected to provide important PK and PD data for potential additional indications of interestRecruitment initiated with dosing anticipated...
► Artikel lesen
23.06.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report4
09.06.Sonnet BioTherapeutics (SONN) Stock Price: Why It Increased Over 19% Today6
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1